The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study
Guo-Qiang Yin, Zu-Lei Li, Dong Li Department of Thoracic Surgery, Zibo Central Hospital, Zibo, Shandong Province, 255000, People’s Republic of ChinaCorrespondence: Dong Li, Department of Thoracic Surgery, Zibo Central Hospital, No. 10 South Shanghai Road, Zibo, Shandong Province, 255000, People’s Re...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-06-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-safety-and-efficacy-of-neoadjuvant-camrelizumab-plus-chemotherapy--peer-reviewed-fulltext-article-CMAR |
| _version_ | 1811229906444484608 |
|---|---|
| author | Yin GQ Li ZL Li D |
| author_facet | Yin GQ Li ZL Li D |
| author_sort | Yin GQ |
| collection | DOAJ |
| description | Guo-Qiang Yin, Zu-Lei Li, Dong Li Department of Thoracic Surgery, Zibo Central Hospital, Zibo, Shandong Province, 255000, People’s Republic of ChinaCorrespondence: Dong Li, Department of Thoracic Surgery, Zibo Central Hospital, No. 10 South Shanghai Road, Zibo, Shandong Province, 255000, People’s Republic of China, Email DongLi552@aliyun.comBackground: Neoadjuvant anti-programmed death receptor-1 (PD-1) blockade has been explored in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). We conducted this study to assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC.Methods: We retrospectively enrolled ESCC patients who received surgery within 3 months of treatment with camrelizumab plus chemotherapy from June 2019 to January 2021.Results: A total of 34 eligible patients were enrolled. The neoadjuvant treatment was well tolerated with no serious treatment-related adverse events. Thirty-two (94.1%) patients achieved a R0 resection, and 14 patients (41.2%) developed postoperative complications. The objective response rate (ORR) was 61.8% and the disease control rate (DCR) was 100.0%. The major pathological response (MPR), pathological complete response (pCR), and clinical to pathological downstaging rate were 50.0%, 35.3%, and 79.4%, respectively. With a median follow-up of 14.8 months, 30 (88.2%) patients who underwent surgical resection remain alive. The disease-free survival (DFS) and overall survival (OS) at 12 months were 86.4% and 92.8%, respectively.Conclusion: Neoadjuvant camrelizumab plus chemotherapy is safe and efficacious in treating patients with locally advanced ESCC.Keywords: esophageal squamous cell carcinoma, neoadjuvant therapy, camrelizumab, chemotherapy, survival |
| first_indexed | 2024-04-12T10:20:09Z |
| format | Article |
| id | doaj.art-5d8bd3af53fa454cb0785d65386fa5b7 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-12T10:20:09Z |
| publishDate | 2022-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-5d8bd3af53fa454cb0785d65386fa5b72022-12-22T03:37:06ZengDove Medical PressCancer Management and Research1179-13222022-06-01Volume 142133214176234The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective StudyYin GQLi ZLLi DGuo-Qiang Yin, Zu-Lei Li, Dong Li Department of Thoracic Surgery, Zibo Central Hospital, Zibo, Shandong Province, 255000, People’s Republic of ChinaCorrespondence: Dong Li, Department of Thoracic Surgery, Zibo Central Hospital, No. 10 South Shanghai Road, Zibo, Shandong Province, 255000, People’s Republic of China, Email DongLi552@aliyun.comBackground: Neoadjuvant anti-programmed death receptor-1 (PD-1) blockade has been explored in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). We conducted this study to assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC.Methods: We retrospectively enrolled ESCC patients who received surgery within 3 months of treatment with camrelizumab plus chemotherapy from June 2019 to January 2021.Results: A total of 34 eligible patients were enrolled. The neoadjuvant treatment was well tolerated with no serious treatment-related adverse events. Thirty-two (94.1%) patients achieved a R0 resection, and 14 patients (41.2%) developed postoperative complications. The objective response rate (ORR) was 61.8% and the disease control rate (DCR) was 100.0%. The major pathological response (MPR), pathological complete response (pCR), and clinical to pathological downstaging rate were 50.0%, 35.3%, and 79.4%, respectively. With a median follow-up of 14.8 months, 30 (88.2%) patients who underwent surgical resection remain alive. The disease-free survival (DFS) and overall survival (OS) at 12 months were 86.4% and 92.8%, respectively.Conclusion: Neoadjuvant camrelizumab plus chemotherapy is safe and efficacious in treating patients with locally advanced ESCC.Keywords: esophageal squamous cell carcinoma, neoadjuvant therapy, camrelizumab, chemotherapy, survivalhttps://www.dovepress.com/the-safety-and-efficacy-of-neoadjuvant-camrelizumab-plus-chemotherapy--peer-reviewed-fulltext-article-CMAResophageal squamous cell carcinomaneoadjuvant therapycamrelizumabchemotherapysurvival |
| spellingShingle | Yin GQ Li ZL Li D The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study Cancer Management and Research esophageal squamous cell carcinoma neoadjuvant therapy camrelizumab chemotherapy survival |
| title | The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study |
| title_full | The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study |
| title_fullStr | The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study |
| title_full_unstemmed | The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study |
| title_short | The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study |
| title_sort | safety and efficacy of neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma a retrospective study |
| topic | esophageal squamous cell carcinoma neoadjuvant therapy camrelizumab chemotherapy survival |
| url | https://www.dovepress.com/the-safety-and-efficacy-of-neoadjuvant-camrelizumab-plus-chemotherapy--peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT yingq thesafetyandefficacyofneoadjuvantcamrelizumabpluschemotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinomaaretrospectivestudy AT lizl thesafetyandefficacyofneoadjuvantcamrelizumabpluschemotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinomaaretrospectivestudy AT lid thesafetyandefficacyofneoadjuvantcamrelizumabpluschemotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinomaaretrospectivestudy AT yingq safetyandefficacyofneoadjuvantcamrelizumabpluschemotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinomaaretrospectivestudy AT lizl safetyandefficacyofneoadjuvantcamrelizumabpluschemotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinomaaretrospectivestudy AT lid safetyandefficacyofneoadjuvantcamrelizumabpluschemotherapyinpatientswithlocallyadvancedesophagealsquamouscellcarcinomaaretrospectivestudy |